Concepedia

Abdulraheem Yacoub

AY

Statistics

Publications

52

Citations

2.4K

H-Index

22

Active since

2014

Affiliations

The University of Kansas Cancer Center(Current)

The University of Texas MD Anderson Cancer Center

Mayo Clinic in Arizona

Icahn School of Medicine at Mount Sinai

Cleveland Clinic

Abdulraheem Yacoub is an author at The University of Kansas Cancer Center specializing in medicine, pharmacology, and pharmacotherapy.

ORCID

Publications per year

2014–2024

52

Publications

52

Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

Steven M. Horwitz, Owen A. O’Connor, Barbara Pro et al. · The Lancet · 2018 · 726 citations · Full text

, , +12

Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea

Abdulraheem Yacoub, John Mascarenhas, Heidi Kosiorek et al. · Blood · 2019 · 171 citations · Full text

, , +5

Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN Study

Ajay K. Gopal, Stephen J. Schuster, Nathan Fowler et al. · Journal of Clinical Oncology · 2018 · 103 citations · Full text

, , +15

Parsaclisib, a potent and highly selective PI3Kδ inhibitor, in patients with relapsed or refractory B-cell malignancies

Andres Forero‐Torres, Radhakrishnan Ramchandren, Abdulraheem Yacoub et al. · Blood · 2019 · 100 citations · Full text

, , +9

The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double‐blind, double‐dummy, symptom study (RELIEF)

Ruben A. Mesa, Alessandro M. Vannucchi, Abdulraheem Yacoub et al. · British Journal of Haematology · 2016 · 88 citations · Full text

, , +8

1–5 of 52